

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT4046986

<b>SUBMISSION TYPE:</b>	CORRECTIVE ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	Corrective Assignment to correct the RECEIVING PARTY DATA previously recorded on Reel 039377 Frame 0186. Assignor(s) hereby confirms the PREVIOUSLY SUBMITTED TYPOGRAPHICAL ERROR.
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
BRISTOL-MYERS SQUIBB COMPANY	02/22/2016
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	VIIV HEALTHCARE UK (NO. 5) LIMITED
<b>Street Address:</b>	980 GREAT WEST ROAD
<b>City:</b>	BRENTFORD, MIDDLESEX
<b>State/Country:</b>	UNITED KINGDOM
<b>Postal Code:</b>	TW89GS
<b>PROPERTY NUMBERS Total: 2</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	13151722
<b>Application Number:</b>	61351332
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(610)270-5090
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	6102706812
<b>Email:</b>	us_cipkop@gsk.com
<b>Correspondent Name:</b>	GLAXOSMITHKLINE
<b>Address Line 1:</b>	709 SWEDELAND ROAD
<b>Address Line 2:</b>	UW2220
<b>Address Line 4:</b>	KING OF PRUSSIA, PENNSYLVANIA 19406
<b>ATTORNEY DOCKET NUMBER:</b>	BMS11542
<b>NAME OF SUBMITTER:</b>	CARLY MORROW
<b>SIGNATURE:</b>	/Carly Morrow/
<b>DATE SIGNED:</b>	09/12/2016
<b>Total Attachments: 9</b>	
source=BMS11542 US Viiv 5 Assignment#page1.tif	
source=BMS11542 US Viiv 5 Assignment#page2.tif	

source=BMS11542 US Viiv 5 Assignment#page3.tif  
source=BMS11542 US Viiv 5 Assignment#page4.tif  
source=BMS11542 US Viiv 5 Assignment#page5.tif  
source=BMS11542 US Viiv 5 Assignment#page6.tif  
source=BMS11542 US Viiv 5 Assignment#page7.tif  
source=BMS11542 US Viiv 5 Assignment#page8.tif  
source=BMS11542 US Viiv 5 Assignment#page9.tif

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3965645

039377 / 0186

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	BRISTOL-MYERS SQUIBB COMPANY	02/22/2016
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	VIIV HEALTHCARE (NO. 5) LIMITED	
<b>Street Address:</b>	980 GREAT WEST ROAD	
<b>City:</b>	BRENTFORD, MIDDLESEX	
<b>State/Country:</b>	UNITED KINGDOM	
<b>Postal Code:</b>	TW89GS	
<b>PROPERTY NUMBERS Total: 2</b>		
	<b>Property Type</b>	<b>Number</b>
	Application Number:	13151722
	Application Number:	61351332
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(610)270-5090	
	<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	6102706812	
<b>Email:</b>	us_cipkop@gsk.com	
<b>Correspondent Name:</b>	GLAXOSMITHKLINE	
<b>Address Line 1:</b>	709 SWEDELAND ROAD	
<b>Address Line 2:</b>	UW2220	
<b>Address Line 4:</b>	KING OF PRUSSIA, PENNSYLVANIA 19406	
<b>ATTORNEY DOCKET NUMBER:</b>	BMS11542	
<b>NAME OF SUBMITTER:</b>	CARLY MORROW	
<b>SIGNATURE:</b>	/Carly Morrow/	
<b>DATE SIGNED:</b>	07/18/2016	
<b>Total Attachments: 54</b>		
source=Viiv 5 assignment#page1.tif		
source=Viiv 5 assignment#page2.tif		
source=Viiv 5 assignment#page3.tif		
source=Viiv 5 assignment#page4.tif		



VIIV Healthcare UK (No.5) Limited  
980 Great West Road  
Brentford  
Middlesex  
TW8 9GS

Bristol-Myers Squibb Company  
345 Park Avenue  
New York, New York 10154-0037

Dear Sirs

**Discovery Patent Assignment Agreement, etc.: correction of typographical errors**

We refer to the Discovery Asset Purchase Agreement dated December 18, 2015 between Bristol-Myers Squibb Company ("BMS") and VIIV Healthcare UK Limited ("VHUK") (the "Discovery APA").

In accordance with the Discovery APA, VHUK nominated VIIV Healthcare UK (No.5) Limited ("VHUK5") as a Buying Affiliate (as defined in the Discovery APA) Pursuant to that nomination, VHUK5 entered into certain Other Transaction Documents (as defined in the Discovery APA), including:

- o the Discovery Patent Assignment Agreement dated February 22, 2016 (the "Assignment Agreement") (as Assignee);
- o the Discovery Intellectual Property License Agreement dated February 22, 2016 (the "License Agreement") (as Buyer); and
- o the Research Services Agreement dated February 22, 2016 (the "Services Agreement") (as Buyer).

Due to a typographical error, VHUK5 was incorrectly named in these Other Transaction Documents as "VIIV Healthcare (No.5) Limited". The same typographical error applies to references to VHUK5 made in other documents entered into in connection with the transactions contemplated by the Discovery APA (including documents to which VHUK5 is not a party).

The purpose of this letter is to confirm that all references to "VIIV Healthcare (No.5) Limited" in Other Transaction Documents (including in particular the Assignment Agreement, the License Agreement and the Services Agreement), or any other document entered into in connection with the transactions contemplated by the Discovery APA, are, and should be read as, references to VIIV Healthcare UK (No.5) Limited.

Yours faithfully

Acknowledged and agreed

Handwritten signature of M.C. Gann in black ink.

for and on behalf of  
VIIV Healthcare UK (No.5) Limited

Handwritten signature of John Rodal in black ink.

for and on behalf of  
Bristol-Myers Squibb Company

www.viivhealthcare.com

Registered in England and Wales  
No 09267335  
Registered Office  
980 Great West Road  
Brentford Middlesex TW8 9GS

**DISCOVERY PATENT ASSIGNMENT AGREEMENT**

This DISCOVERY PATENT ASSIGNMENT AGREEMENT (this "Agreement") is made as of February 22, 2016, by BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation ("Assignor") in favor of VIIV HEALTHCARE (NO. 5) LIMITED, a limited liability company registered in England and Wales ("Assignee").

WHEREAS, Assignor and Assignee are parties to that certain Discovery Asset Purchase Agreement, effective as of December 18, 2015, by and between Assignor and Assignee (the "Purchase Agreement"),

WHEREAS, capitalized terms used herein but not otherwise defined shall have the meanings ascribed to such terms in the Purchase Agreement;

WHEREAS, pursuant to the Purchase Agreement, Assignor agreed to sell, assign, transfer, convey, and deliver to Assignee, and Assignee agreed to purchase, acquire and accept from Assignor, certain intellectual property as defined therein; and

WHEREAS, Assignor is the owner and/or applicant for registration of certain Patents specifically identified in Schedule A attached hereto (the "Assigned Patents"),

NOW, THEREFORE, in consideration of the foregoing and in consideration of the mutual promises, covenants, representations, warranties and agreements contained herein and in the Purchase Agreement, for good and valuable consideration, the receipt of which is hereby acknowledged, Assignor and Assignee hereby agree as follows:

1. Assignment. Effective as of the date hereof, and pursuant to the Purchase Agreement, Assignor hereby sells, assigns, transfers, conveys, and delivers to Assignee all of Assignor's right, title and interest in, to and under all Assigned Patents, including, without limitation, any reissues, divisions/divisionals, continuations, continuations-in-part, extensions, provisional or supplemental protection certificates, renewals and reexaminations thereof, all corresponding rights that are or may be secured under the laws of the United States or any foreign country, now or hereafter arising or in effect, including the right to claim priority from the Assigned Patents under the Paris Convention for the Protection of Industrial Property, and under any and all other such treaties and agreements to which the United States is a party and which afford similar priority-claiming privileges, throughout the world, for Assignee's own use and enjoyment, and for the use and enjoyment of Assignee's successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Agreement had not been made, together with the right to collect royalties, products and proceeds in connection with any of the foregoing and the right to sue for any past, present or future infringement, misappropriation or other violation thereof and to collect and retain all damages and profits related to the foregoing, and any priority right that may arise from any such Assigned Patents

2. Recordation Assignor hereby consents to and authorizes the United States Patent and Trademark Office or any other governmental office or agency in each jurisdiction other than the United States to record this Agreement and to issue any and all patents or certificates of

invention which may be granted upon any of the Assigned Patents in the name of Assignee, as the assignee to the entire interest therein. Assignee shall have the right to file patent applications included in the Assigned Patents in any country.

3. Further Acts. Assignor will assist Assignee (at Assignee's sole cost and expense) in connection with any such recording, and shall duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things necessary or useful for the procurement, maintenance, enforcement and defense of any Assigned Patent, or for any proceeding, including interference, opposition proceedings, post-issuance patent challenges and other proceedings under the U.S. Leahy-Smith America Invents Act, in each case in connection with any Assigned Patent in any country, including the filing of such assignments, agreements, documents and instruments, but, in each case, only if and to the extent Assignee may reasonably request in order to fulfill the purposes and intent of this Agreement. Assignor shall promptly forward to Assignee any correspondence or other communication from any patent office or any counsel employed by Assignor in connection with any of the Assigned Patents

4. Conflicts. In the event of any conflict, ambiguity or inconsistency between the terms set out in this Agreement and the Purchase Agreement (including, without limitation, any schedule hereto or thereto), the terms of the Purchase Agreement shall govern and control, including with regard to any representations, warranties, covenants, or indemnities included in the Purchase Agreement.

5. Successors This Agreement and all of the provisions hereof will be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns.

6. Counterparts. This Agreement may be executed in one or more counterparts (including by means of telecopied portable document format (pdf) signature pages), any one of which need not contain the signatures of more than one Party, but all such counterparts taken together shall constitute one and the same agreement.


7. Governing Law. All questions concerning the construction, validity and interpretation of this Agreement, including Schedule A hereto, will be governed by and construed in accordance with the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision that would cause the application of the laws of any jurisdiction other than the State of New York

[Signature page follows]

**IN WITNESS WHEREOF**, Assignor and Assignee have caused this Agreement to be duly executed by its authorized representative as of the day and year first above written.

**ASSIGNOR:**

**BRISTOL-MYERS SQUIBB COMPANY**

By. 

Name: Paul R. Biondi

Title: Senior Vice President, Business  
Development

IN WITNESS WHEREOF, Assignor and Assignee have caused this Agreement to be duly executed by its authorized representative as of the day and year first above written.


ASSIGNOR:

BRISTOL-MYERS SQUIBB COMPANY

By: \_\_\_\_\_  
Name:  
Title:

ASSIGNEE:

VIIV HEALTHCARE (NO. 5) LIMITED

By:   
Name: \_\_\_\_\_  
Title: Jerome Andries  
CFO Viiv Healthcare



Docket No.	Country	Filing No.	Filing Date	Grant No.	Grant Date	Case Status
11432-NL-EPT	Netherlands					Designated
11432-NO-EPT	Norway					Designated
11432-PL-EPT	Poland					Designated
11432-PT-EPT	Portugal					Designated
11432-RO-EPT	Romania					Designated
11432-RS-EPT	Serbia (ex-Serbia & Montenegro)					Designated
11432-SE-EPT	Sweden					Designated
11432-SI-EPT	Slovenia					Designated
11432-SK-EPT	Slovakia					Designated
11432-SM-EPT	San Marino					Designated
11432-TR-EPT	Turkey					Designated
11432-TW-NP	Taiwan	100119644	03 Jun 2011			Abandoned
11432-US-NP	United States Of America	13/151706	02 Jun 2011	8754068	17 Jun 2014	Grant
11432-US-PSP	United States Of America	61/245332	24 Sep 2009			Abandoned
11432-US-PSP[2]	United States Of America	61/351338	04 Jun 2010			Expiry date
11432-WO-PCT	International Procedure	PCT/US2011/038879	02 Jun 2011			PCT CONVERTED

Docket No.	Country	Filing No.	Filing Date	Grant No.	Grant Date	Case Status
<b>Title: C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS</b>						
11542-AL-EPT	Albania	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-AR-NP	Argentina	P110101945	31 Mar 2011			Abandoned
11542-AT-EPT	Austria	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-BE-EPT	Belgium	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-BG-EPT	Bulgaria	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-BR-PCT	Brazil	112012030810 6	02 Jun 2011			Local filing
11542-CA-PCT	Canada	2801491	02 Jun 2011			Local filing

Docket No.	Country	Filing No.	Filing Date	Grant No.	Grant Date	Case Status
11542-CH-EPT	Switzerland	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-CN-PCT	China	201180035812 4	02 Jun 2011			Publication of application
11542-CY-EPT	Cyprus (Republic)	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-CZ-EPT	Czech Republic	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-DE-EPT	Germany	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-DK-EPT	Denmark	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-EA-EAT	Eurasian Procedure	201270800	02 Jun 2011			Local filing
11542-EE-EPT	Estonia	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-EP-EPT	European Procedure (Patents)	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-ES-EPT	Spain	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-FI-EPT	Finland	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-FR-EPT	France	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-GB-EPT	United Kingdom	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-GR-EPT	Greece	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-HR-EPT	Croatia	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-HU-EPT	Hungary	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-IE-EPT	Ireland	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-IN-PCT	India	10038/CHENP/12	02 Jun 2011			Publication of application
11542-IS-EPT	Iceland	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-IT-EPT	Italy	11726564 5	02 Jun 2011	502015000066399	12 Aug 2015	Grant
11542-JP-PCT	Japan	2013-513340	02 Jun 2011	5755731	05 Jun 2015	Grant
11542-LT-EPT	Lithuania	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-LU-EPT	Luxembourg	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-LV-EPT	Latvia	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-MC-EPT	Monaco	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-MK-EPT	Macedonia (F Y R )	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant

Docket No.	Country	Filing No.	Filing Date	Grant No.	Grant Date	Case Status
11542-MT-EPT	Malta	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-MX-PCT	Mexico	MX/A/12/013628	02 Jun 2011	313688	27 Sep 2013	Grant
11542-NL-EPT	Netherlands	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-NO-EPT	Norway	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-PL-EPT	Poland	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-PT-EPT	Portugal	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-RO-EPT	Romania	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-RS-EPT	Serbia (ex-Serbia & Montenegro)	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-SE-EPT	Sweden	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-SI-EPT	Slovenia	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-SK-EPT	Slovakia	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-SM-EPT	San Marino	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-TR-EPT	Turkey	11726564 5	02 Jun 2011	2576586	12 Aug 2015	Grant
11542-TW-NP	Taiwan	100119710	03 Jun 2011			Abandoned
11542-US-NP	United States Of America	13/151722	02 Jun 2011	8802661	12 Aug 2014	Grant
11542-US-PSP	United States Of America	61/351332	04 Jun 2010			Expiry date
11542-WO-PCT	International Procedure	PCT/US2011/038884	02 Jun 2011			PCT CONVERTED

Docket No.	Country	Filing No.	Filing Date	Grant No.	Grant Date	Case Status
<b>Title: C-28 AMINES OF C-3 MODIFIED BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS</b>						
11653-AL-EPT	Albania	12702946 0	27 Jan 2012	2670764	02 Sep 2015	Grant
11653-AT-EPT	Austria	12702946 0	27 Jan 2012	2670764	02 Sep 2015	Grant
11653-BE-EPT	Belgium	12702946 0	27 Jan 2012	2670764	02 Sep 2015	Grant
11653-BG-EPT	Bulgaria	12702946 0	27 Jan 2012	2670764	02 Sep 2015	Grant
11653-BR-PCT	Brazil	112014010105 1	27 Jan 2012			Local filing
11653-CA-PCT	Canada	2,826,257	27 Jan 2012			Local filing